Cancer Therapy

Study data from Ocean University of China, Marine Drug and Food Institute provide new insights into HIV/AIDS cancer therapy

Cancer Therapy Library Library Home This article was published in AIDS Weekly, which you can subscribe to online.

"Mounting evidence further suggests that multiple angiogenic activities of Tat contribute to AIDS-associated Kaposi's sarcoma (AIDS-KS). Herein, we report that sulfated polymannuroguluronate (SPMG), a novel anti-AIDS drug candidate now undergoing phase II clinical trial, significantly eliminated Tat-induced angiogenesis in SLK cells both in vitro and in vivo. SPMG significantly and dose-dependently inhibits proliferation, migration, and tube formation by SLK cells. SPMG also dramatically arrested Tat-driven KDR phosphorylation and blocked the interaction between Tat and integrin beta1, thus inhibiting the phosphorylation of the downstream kinases of FAK, paxillin and MAPKs. In addition, SPMG was noted to block the release of bFGF and VEGF from ECM," wrote C.X. Lu and colleagues, Ocean University of China, Marine Drug and Food Institute.

The researchers concluded: "All these collectively favor an issue that SPMG functions as a promising therapeutic against Tat-induced angiogenesis and pathologic events relevant to AIDS-KS, which adds novel mechanistic profiling to the anti-AIDS action of SPMG."

Lu and colleagues published their study in Biochemical Pharmacology (Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. Biochemical Pharmacology, 2007;74(9):1330-9).

For additional information, contact C.X. Lu, Yantai Yuhuangding Hospital, Yantai 264000 and Dept. of Molecular Pharmacology, Yantai Yuhuangding Hospital, Marine Drug and Food Institute, School of Medicine and Pharmacy, Ocean University of China, Qingdao, PR China.

Publisher contact information for the journal Biochemical Pharmacology is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

Keywords: People's Republic of China, Qingdao, HIV/AIDS Cancer Therapy, AIDS, Acquired Immunodeficiency Syndrome, Angiogenesis, Biochemical Pharmacology, Clinical Trial Research, Drug Development, Drugs, HIV, Human Immunodeficiency Virus Cancer, Kaposi Sarcoma, Oncology, Pharmaceuticals, Pharmacology, Therapies, Therapy, Treatment, Tumor Vascularization, Virology.

This article was prepared by AIDS Weekly editors from staff and other reports. Copyright 2007, AIDS Weekly via NewsRx.com.